Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lauflumide - NewcelX

Next Previous
Drug Profile

Lauflumide - NewcelX

Alternative Names: NLS-14; NLS-4

Latest Information Update: 05 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroLifeSciences
  • Developer NewcelX; NLS Pharmaceutics Ltd; University of Lausanne
  • Class Behavioural disorder therapies; Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic fatigue syndrome
  • No development reported Idiopathic hypersomnia
  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Narcolepsy

Most Recent Events

  • 30 Oct 2025 Kadimastem has merged with NLS Pharmaceutics Ltd to form NewcelX
  • 28 Jan 2024 No recent reports of development identified for preclinical development in Idiopathic-hypersomnia in Switzerland
  • 09 Oct 2023 Discontinued - Preclinical for Narcolepsy in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top